DUBLIN – June 2nd, 2015 – Aalto Bio Reagents is delighted to announce the availability of our new recombinant Chikungunya E2 wild type (Aalto code BM6284), recombinant Chikungunya E1mutant (Aalto code BM6295) and recombinant Chikungunya E1 wild type (Aalto code BM6300) antigens. These antigens have proven to work very well in ELISA applications.
Chikungunya virus is a mosquito-borne, arthrogenic alphavirus that causes large epidemics in Africa, South East Asia and India. In these warm climates, the virus is transmitted by Aedes aegypti. Symptoms of the disease generally start 4 – 7 days after the bite of the infected mosquito. Acute infection lasts for 1 – 10 days and is characterised by a painful polyarthralgia, high fever, asthenia, headache, vomiting, rash and myalgia.
Recently, Chikungunya virus has been transmitted to humans in North America and Southern Europe by the now established Asian tiger mosquitoes (Aedes albopictus). A specific mutation of the glycoprotein E1 (exchange of alanine 226 against valine) allows the virus to infect Aedes albopictus which is prevalent in the more temperate European climate and thus, is of more relevance to us here in Europe or North America.
We continue to supply our recombinant Chikungunya E1 wild type (Aalto code AZ6271) and recombinant Chikungunya E1 mutant (Aalto code AZ6267) antigens for lateral flow type rapid test.
For further information contact:
For direct product information: